Ahsan Syed1, Matthew D Sadler1, Meredith A Borman1, Kelly W Burak1, Stephen E Congly1,2. 1. Division of Gastroenterology and Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. 2. O'Brien Institute of Public Health, University of Calgary, Calgary, Alberta, Canada.
Abstract
Background: When last assessed in 2013, all Canadian liver transplant programs required 6 months of abstinence from alcohol. New studies have questioned the validity of this policy. Moreover, with recreational cannabis now legal in Canada, more transplant candidates may use cannabis. Given these changes, our objective was to obtain an understanding of current Canadian practices regarding liver transplantation and candidates with addiction or alcohol, tobacco, cannabis, or opiate use. Methods: Electronic surveys were distributed to the medical directors of all seven adult liver transplant programs in Canada. Questions were based on either a Likert-scale ranking or free response. The complete data set was aggregated to provide a national perspective on this topic and ensure each individual program remained anonymous. Results: All seven programs responded to the survey. Of these programs, 43% always require 6-month abstinence from alcohol, 29% usually require it, and 14% sometimes require it. Formal alcohol rehabilitation is mandatory in two programs. The majority (57%) of programs never or rarely consider transplant for patients with acute alcoholic hepatitis; 29% require smoking cessation before consideration for transplant; and 71% felt that cannabis use is rarely or never a contraindication to liver transplantation. Conclusions: Significantly more Canadian programs now perform liver transplant for patients who have less than 6 months abstinence from alcohol, and alcoholic hepatitis is no longer an absolute contraindication in Canada. Policies on smoking and opiates are quite variable. Further study and discussion are critical for development of national policies to obtain equitable access to liver transplant for all.
Background: When last assessed in 2013, all Canadian liver transplant programs required 6 months of abstinence from alcohol. New studies have questioned the validity of this policy. Moreover, with recreational cannabis now legal in Canada, more transplant candidates may use cannabis. Given these changes, our objective was to obtain an understanding of current Canadian practices regarding liver transplantation and candidates with addiction or alcohol, tobacco, cannabis, or opiate use. Methods: Electronic surveys were distributed to the medical directors of all seven adult liver transplant programs in Canada. Questions were based on either a Likert-scale ranking or free response. The complete data set was aggregated to provide a national perspective on this topic and ensure each individual program remained anonymous. Results: All seven programs responded to the survey. Of these programs, 43% always require 6-month abstinence from alcohol, 29% usually require it, and 14% sometimes require it. Formal alcohol rehabilitation is mandatory in two programs. The majority (57%) of programs never or rarely consider transplant for patients with acute alcoholic hepatitis; 29% require smoking cessation before consideration for transplant; and 71% felt that cannabis use is rarely or never a contraindication to liver transplantation. Conclusions: Significantly more Canadian programs now perform liver transplant for patients who have less than 6 months abstinence from alcohol, and alcoholic hepatitis is no longer an absolute contraindication in Canada. Policies on smoking and opiates are quite variable. Further study and discussion are critical for development of national policies to obtain equitable access to liver transplant for all.
Authors: W R Kim; J R Lake; J M Smith; D P Schladt; M A Skeans; S M Noreen; A M Robinson; E Miller; J J Snyder; A K Israni; B L Kasiske Journal: Am J Transplant Date: 2019-02 Impact factor: 8.086
Authors: Giovanni Addolorato; Ramón Bataller; Patrizia Burra; Andrea DiMartini; Ivo Graziadei; Michael R Lucey; Philippe Mathurin; John OʼGrady; Georges Pageaux; Marina Berenguer Journal: Transplantation Date: 2016-05 Impact factor: 4.939
Authors: Saroja Bangaru; Mark R Pedersen; Malcolm P MacConmara; Amit G Singal; Arjmand R Mufti Journal: Liver Transpl Date: 2018-10 Impact factor: 5.799
Authors: Brian P Lee; Eric Vittinghoff; Jennifer L Dodge; Giuseppe Cullaro; Norah A Terrault Journal: JAMA Intern Med Date: 2019-03-01 Impact factor: 21.873